


La molécule du mois - What molecule am I ?



ABX464

ABX464 is a first-in-class oral small molecule inhibiting HIV replication through a novel mechanism which lead to the destruction of viral RNA. ABX464 can inhibit a small viral protein essential for viral gene expression: the Rev protein. This promising molecule is currently in Phase II for an antiviral therapy for patients with HIV infection. ABX464 is developed by a french biotechnology company (ABIVAX).

For an animated description of the mode of action of ABX464, see :

<https://www.youtube.com/watch?v=qh3-MOEskJY>

Contribution : David MONTOR February 2016